UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, DC 20549
FORM
12b-25
NOTIFICATION OF LATE FILING
Commission File
Number 000-22179
(Check One): [ ] Form 10-K [
] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form
10D
[ ] Form N-SAR [
] Form N-CSR
For Period
Ended: June 30,
2017
[ ]
|
|
Transition Report on Form 10-K
|
[ ]
|
|
Transition Report on Form 20-F
|
[ ]
|
|
Transition Report on Form 11-K
|
[ ]
|
|
Transition Report on Form 10-Q
|
[ ]
|
|
Transition Report on Form N-SAR
|
For the Transition
Period Ended: ___________________
Nothing in this form shall be construed to
imply that the Commission has verified any information contained
herein.
If the notification relates to a portion of the
filing checked above, identify the Item(s) to which the
notification relates:
_______________________________________________
|
PART
I
REGISTRANT INFORMATION
Full Name of
Registrant: Guided
Therapeutics, Inc.
Address of
Principal Executive
Office (Street and number):
5835 Peachtree
Corners East, Suite D
City, State and Zip
Code: Norcross,
Georgia 30092
1
PART II
RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if
appropriate)
|
(a) The reasons described in reasonable detail
in Part III of this form could not be eliminated without
unreasonable effort or expense;
|
[X]
|
(b) The subject annual report, semi-annual
report, transition report on Form 10-K, Form 20-F, 11-K, Form
N-SAR, or Form N-CSR, or portion thereof, will be filed on or
before the fifteenth calendar day following the prescribed due
date; or the subject quarterly report or transition report on Form
10-Q, or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
|
|
(c) The accountant's statement or other exhibit
required by Rule 12b-25(c) has been attached if
applicable.
|
PART
III
NARRATIVE
State below in
reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, N-CSR or the transition report or portion thereof, could not
be filed within the prescribed time period.
The
registrant’s quarterly report on Form 10-Q could not be filed
within the prescribed time period. During the second quarter of
2017 (as in the first quarter of 2017), the registrant continued to
experience considerable financial constraints. These financial
constraints have postponed the ability of the registrant’s
auditors from reviewing the Form 10-Q and in starting the Financial
review process and thus resulted in delays in the preparation and
presentation of financial information. These delays contributed to
the registrant’s inability to process and review the
financial information required to file the quarterly report on Form
10-Q by the date required without incurring undue hardship and
expense.
The registrant
expects to file its Form 10-Q within the permitted extension
period.
PART IV
OTHER INFORMATION
(1) Name and
telephone number of person to contact in regard to this
notification
|
|
Gene S.
Cartwright
|
|
(770)
|
|
242-8723
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
|
|
|
|
|
2
(2) Have all other
periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If answer is no, identify
report(s).
Yes [X ] No [
]
(3) Is it
anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof?
Yes [ ] No [X
]
If so, attach an
explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
Guided Therapeutics, Inc.
(Name of Registrant as
Specified in Charter)
has caused this
notification to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
Date: August 15, 2017
|
By: /s/
Gene S. Cartwright
|
|
Gene S.
Cartwright
President and Chief
Executive Officer
|
3